Amarin Plunges After Vascepa Patents Are Invalidated

(Bloomberg) -- Amarin Corp. plunged in after-hours trading after a U.S. judge invalidated its patents on the heart treatment Vascepa, opening the door to low-cost versions of a drug that accounts f...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.